BridgeMD
The OPTIMIST study
EU CTIS ID: 2023-505940-20-00
What this study is testing
The main objective of the OPTIMIST study is to identify the optimal use of romosozumab for the treatment of osteoporosis by investigating 3 different treatment strategies.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- postmenopausal women
- Osteoporosis defined as BMD T-score < -2.5 at spine, total hip or femoral neck
- Osteoporotic fracture at spine, hip, pelvis, forearm, or humerus within 3 years after the age of 50 years
You likely can't join if
- Osteoporosis treatment within the last 5 years
- Metabolic bone disease
- Known disorders affecting bone metabolism
- Ongoing treatment with glucocorticoids
- Estimated glomerular filtration rate (eGFR) < 35 ml/min
- Contraindications or intolerance to romosozumab or zoledronate
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.